They’re Cardiovascular Drugs. And We’re Still Treating Them Wrong.**
GLP-1 drugs should not be seen as weight loss medications. They are meant to treat cardiovascular conditions.
Most of the medical field has not yet recognized this shift.
Patients are missing out because there is a gap between what the evidence shows and how these drugs are used in practice.
This creates a cycle: when a therapy is misunderstood, it is prescribed and reimbursed for the wrong reasons, and its true value is overlooked.
This is exactly what has happened with GLP-1 receptor agonists. The issue is not only about clinical progress, but also about how we think about these drugs.
The moment that should have changed everything
The key moment came in November 2023, when the SELECT trial results were published. At first, it seemed like just another large, well-designed cardiovascular study. But a closer look at the trial design revealed something important.
This was not a diabetes study. The trial included more than 17,000 people with cardiovascular disease and a BMI over 27, regardless of whether they had diabetes. That fact alone should have caught our attention.
Before this, most cardiovascular benefits from GLP-1 drugs were seen in people with type 2 diabetes. This raised the question: are these benefits only due to better glucose control?
SELECT answered that question directly.
Patients were randomly assigned to receive either semaglutide 2.4 mg or a placebo. The main outcome measured was not weight loss, but major adverse cardiovascular events such as heart attack, stroke, or cardiovascular death.
After about three years, the results were clear.
There was a 20% relative reduction in major cardiovascular events(MACE). For a therapy used to prevent further heart problems, this is a significant result.
Yet, most public discussions after the trial still focused mainly on weight loss.
By now, you can see the issue with how these drugs are being framed.
We are still focusing on the wrong question.
Most people think about GLP-1 drugs by asking one main question:
“How much weight will I lose?”
This is a fair question. Weight is easy to see, measure, and has an emotional impact. But it is actually the least important aspect of these drugs. Weight loss is a result, not the main way the drugs work.
The pertinent question to ask is:
What is happening biologically that leads to both weight loss and cardiovascular risk reduction?
And the answer is: quite a lot.
GLP-1 receptor agonists affect several systems at once. They lower inflammation throughout the body, improve the health of blood vessel linings, slightly reduce blood pressure, change how the body manages glucose and insulin, and decrease visceral fat, which is closely linked to heart disease.
None of these effects are just cosmetic. They are directly related to how heart disease starts and gets worse.
When we call this just a weight loss drug, we ignore its complex effects on the body and focus only on one visible result. By doing this, we miss the real value.
This wasn’t a weight loss study with heart benefits.
There is a subtle but important distinction that is often overlooked. SELECT did not show that a weight loss drug helps the heart.
Instead, it showed that a cardiovascular drug can also lead to weight loss. This change in perspective is important because it affects how we use the therapy.
If you see it as a weight loss drug, you might only prescribe it after lifestyle changes fail, when BMI is high enough, or when a patient requests it.
But if you view it as a cardiovascular drug, you prescribe it based on the patient’s risk, just as you would with statins, ACE inhibitors, or beta-blockers.
The reason for prescribing shifts from appearance or metabolic improvement to actually reducing risk and preventing events. This is a major change in clinical thinking.
The adoption gap in cardiology
This is where things start to get interesting.
When a patient has coronary artery disease, starting a high-intensity statin is routine and expected. It follows standard protocols.
But if the same patient, with the same health issues and a higher BMI, is given a GLP-1 receptor agonist, doctors often hesitate.
Sometimes it’s framed as a scope issue: “This belongs to endocrinology.”
Sometimes it’s an insurance issue: “This won’t be covered.”
Sometimes it’s a perception issue: “Is this really necessary?”
At the root of all these concerns is how we frame the use of these drugs.
Most cardiologists see these drugs as tools for metabolism, not as treatments for heart disease. This leads to hesitation, which can have serious consequences.
Cardiovascular disease does not pause while doctors sort out their roles. It moves forward quietly, driven by many risk factors. The more tools we have to fight these risks, the more carefully we should use them.
Where GLP-1 fits, and where it doesn’t
There is another common misunderstanding that needs to be addressed.
Reframing GLP-1 drugs as cardiovascular therapies does not mean they replace existing treatments.
They definitely do NOT. They do not replace statins in patients with established atherosclerotic disease. They do not replace blood pressure control. They do not replace structured exercise or improvements in cardiorespiratory fitness. They do not replace targeted lipid management, including ApoB reduction.
These drugs are not a shortcut or a replacement for other treatments. They are a powerful addition, but still just one part of a larger treatment plan.
Good heart care has never relied on just one treatment. It is about combining the right treatments for the right patient at the right time. GLP-1 agonists are part of that combination.
What this looks like in real clinical decisions
When I consider prescribing a GLP-1 receptor agonist, I start by looking at the patient’s risk, not their weight.
The questions I ask are:
Does this patient have established cardiovascular disease?
Is there evidence of metabolic dysfunction?
Are there modifiable drivers that are not being adequately addressed with current therapy?
If the answers are yes, then GLP-1 is not just an optional extra, but a real treatment for heart disease.
I explain this to my patients by saying that, yes, this medicine will probably help with weight, which is a clear benefit.
But that is not the main reason I prescribe it. I prescribe it for the same reason as a statin: it has been proven to lower the risk of heart attack and death from heart disease in patients like them.
Changing how we talk about the drug helps patients see it as essential, not just optional.
When patients see the drug as essential, they are more likely to stick with it.
The deeper shift: from treatment to precision
The SELECT trial does more than just confirm the value of this drug class. It moves us toward a more precise way of treating heart disease.
For years, treatment has followed a standard approach: lower LDL, control blood pressure, and encourage lifestyle changes.
These steps are still foundational. But we now realize that heart risk is complex and involves many factors, like cholesterol, inflammation, metabolism, blood vessel health, body composition, and fitness.
No single treatment can address all these areas. GLP-1 receptor agonists are unique because they impact several of them at once.
This does not mean they are a cure, but it does make them a valuable part of a broader treatment plan.
The future of heart care is not about picking one treatment over another, but about combining them wisely.
Why the framing matters more than we think
It’s easy to dismiss it as mere wording.
Does it really matter if we call it a weight-loss drug or a cardiovascular drug?
It does.
Because labels shape behavior. They affect which patients are considered eligible, how physicians prioritize therapies, how insurers decide what to cover, and, most importantly, how patients perceive value.
Right now, the label is lagging behind the evidence. And until that catches up, adoption will remain uneven.
The real takeaway
The most important takeaway from the SELECT trial is not the 20% risk reduction. It is the redefinition of what this class of drugs actually is.
In GLP-1 receptor agonists, we are not looking at a better weight-loss medication. We are looking at a cardiovascular therapy that happens to improve weight, metabolism, and systemic inflammation along the way.
This difference should change our thinking, prescribing, and priorities. The real goal is not just weight loss, but better heart care, fewer heart attacks and strokes, and a longer, healthier life.
When a drug truly makes a difference, we should stop asking “Is it just for weight loss?”
Instead, we should ask: Why aren’t we using it more for the patients who could benefit the most?”
